|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009566,
umls-concept:C0016059,
umls-concept:C0017262,
umls-concept:C0021368,
umls-concept:C0030705,
umls-concept:C0087086,
umls-concept:C0185117,
umls-concept:C0231220,
umls-concept:C0332461,
umls-concept:C0427579,
umls-concept:C0441509,
umls-concept:C0449774,
umls-concept:C1300562,
umls-concept:C1415938,
umls-concept:C2348205,
umls-concept:C2745888,
umls-concept:C2911684,
umls-concept:C2931689
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2004-8-17
|
|
pubmed:abstractText |
One of the possible pathological mechanisms behind the increased vascular injury in diabetes mellitus type 2 (DM2) is the formation of advanced glycation end products (AGEs). The aim of this study was to investigate whether the presence of AGEs and specific markers for coagulation and inflammation in symptomatic atherosclerotic plaques from DM2 patients differs from plaques from nondiabetics.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0022-1554
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright The Histochemical Society, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1141-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15314081-Aged,
pubmed-meshheading:15314081-Arteriosclerosis,
pubmed-meshheading:15314081-Biological Markers,
pubmed-meshheading:15314081-Blood Coagulation Tests,
pubmed-meshheading:15314081-Cell Nucleus,
pubmed-meshheading:15314081-Diabetes Mellitus, Type 2,
pubmed-meshheading:15314081-Female,
pubmed-meshheading:15314081-Fibrosis,
pubmed-meshheading:15314081-Humans,
pubmed-meshheading:15314081-Immunohistochemistry,
pubmed-meshheading:15314081-Inflammation,
pubmed-meshheading:15314081-Male,
pubmed-meshheading:15314081-NF-kappa B,
pubmed-meshheading:15314081-Thrombosis
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
More fibrosis and thrombotic complications but similar expression patterns of markers for coagulation and inflammation in symptomatic plaques from DM2 patients.
|
|
pubmed:affiliation |
Laboratory of Experimental Internal Medicine, G2-108, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. d.w.sommeijer@amc.uva.nl
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
